Evotec (EVO)
(Delayed Data from NSDQ)
$4.13 USD
+0.01 (0.24%)
Updated Oct 28, 2025 04:00 PM ET
After-Market: $4.13 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Evotec AG has a PEG ratio of 0.23 compared to the Medical - Drugs industry's PEG ratio of 1.17.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVO 4.13 +0.01(0.24%)
Will EVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EVO based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for EVO
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
EVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for EVO
Is EVO positioned for a breakout? Expansion Breakout shows up after climbing 0.49%
Evolution AB Enhances Capital Structure with Share Repurchase
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
EVO forms NR7 on October 24
Evolution Gaming Group AB (EVO) Gets a Sell from J.P. Morgan